Received Apr 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 3C423 | — |
pain at the injection site; Injection site swelling; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 4-year-old male patient who received DTPa-IPV (Kinrix) (batch number 3C423, expiry date 06-SEP-2027) for prophylaxis. On 20-APR-2026, the patient received Kinrix. In APR-2026, an unknown time after receiving Kinrix, the patient experienced injection site pain (Verbatim: pain at the injection site) and injection site swelling (Verbatim: Injection site swelling). The outcome of the injection site pain and injection site swelling were unknown. It was unknown if the reporter considered the injection site pain and injection site swelling to be related to Kinrix and Kinrix Pre-Filled Syringe Device. It was unknown if the company considered the injection site pain and injection site swelling to be related to Kinrix and Kinrix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-APR-2026 The patient was complaining of pain at the injection site and swelling.